At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
AZD4831 Oral Myeloperoxidase Inhibitor +1 moredrug
Likely dose
AZD4831 30 mg oral, single dose given during right heart catheterizationAI-extracted
Key inclusion· 4
- ✓Age ≥30 years
- ✓Dyspnea symptoms NYHA Class II-IV
- ✓Ejection fraction ≥50% within 12 months of enrollment
- ✓Catheterization-documented elevated filling pressures: PCWP ≥15 mmHg at rest or ≥25 mmHg with exercise
Key exclusion· 13
- ✕Nitrates, phosphodiesterase 5 inhibitors, or other NO-providing therapy within 24 hours of screening
- ✕Significant valvular disease: >moderate left-sided regurgitation or >mild stenosis
- ✕Requirement of intravenous heparin at start of case
- ✕Severe pulmonary parenchymal disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hemodynamic Effects of a Novel Myeloperoxidase Inhibitor With Exercise in Heart Failure With Preserved Ejection Fraction - A Randomized, Double-Blind, Placebo Controlled Proof of Principle Study
In Brief
A Phase 2 clinical trial evaluating AZD4831 Oral Myeloperoxidase Inhibitor and Placebo oral capsule for Heart Failure. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedAug 2018
Primary CompletionFeb 2022
Study CompletionFeb 2022
TodayJul 2026
First PostedAug 2, 2018
Enrollment StartJul 1, 2018
Primary CompletionFeb 11, 2022
Study CompletionFeb 24, 2022
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 7.9 years ago
Interventions
AZD4831 Oral Myeloperoxidase Inhibitordrug
A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
Placebo oral capsuledrug
A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.